IHS Chemical Week

EnviroTech :: Biotech

Sanofi-Aventis Signs Licensing Agreement with U.S. Biotech Firm

4:14 AM MDT | October 2, 2009 | Deepti Ramesh

Sanofi-Aventis (Paris) says it has entered into an exclusive global collaboration and licensing agreement with biotechnology company Merrimack Pharmaceuticals (Cambridge, MA) for MM-121, a monoclonal antibody in oncology. MM-121 is currently in Phase 1 clinical testing. Sanofi-Aventis will receive an exclusive worldwide license to develop, manufacture and commercialize MM-121, under the terms of the deal. Merrimack will retain potential co-promotion rights in the U.S. MM-121 is a pioneering monoclonal antibody which brings a new innovative approach to...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa